"In the Spotlight: LinXis technology discussed in Dutch medical oncology journal"

Read more

Mission

Our mission is to create antibody-drug conjugates that are effective, safe, and affordable.

A small number of antibody-drug conjugates have thus far been approved for human use, confirming that the antibody-drug concept is viable. Practically however, they fail to reach many patients in need. On the one hand, this is due to their cost - their complex development and manufacturing processes make for a very high price. On the other hand, this is due to their disappointing safety and efficacy.

The goal of LinXis is to deliver on the initial promise of antibody-drug conjugates - by creating these medicines at low development- and manufacturing cost, with a favorable safety and efficacy profile, and for diseases that represent a world-wide and unmet medical need.

LinXis operates in alignment with the United Nations Sustainable Development Goals.